Dr McAndrew on the Implications of the PHERGain Study in HER

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

Related Keywords

California , United States , Los Angeles , Nicholasp Mcandrew , , University Of California , Ucla Health Jonsson Comprehensive Cancer Center , Onclive Tv , Neoadjuvant Her2 , Breast Cancer , Nct03161353 ,